Board of Directors
THOMAS J. HAUGHEY, Chairman of the Board
Mr. Haughey has been a member of the Board since May 2018 and has served as Chairman of the Board since November 2025. Mr. Haughey held the role of General Counsel and Secretary at Par Pharmaceutical Companies, Inc. (“Par”) from 2003 through 2016. In addition to his role as General Counsel, he has held various additional executive roles at Par, including President from 2011 to 2012 and Chief Administrative Officer from 2012 to 2016. Prior to that, Mr. Haughey held positions at Schering-Plough Corporation, where he was Chief Counsel from 1998 to 2001 and Legal Director from 2001 to 2003. Previously, Mr. Haughey was an attorney at Cadwalader Wickersham & Taft and a certified public accountant at Arthur Anderson & Co. Mr. Haughey earned a B.S. in accounting at St. John’s University and a J.D. at the New York University School of Law.
Chairman of the Board
Member of the Audit and Finance Committee
Member of the Nominating and Corporate Governance Committee
NIKHIL LALWANI, Director and President and CEO
Mr. Lalwani is ANI’s President and Chief Executive Officer and a member of ANI’s Board. Prior to joining ANI in September 2020, Mr. Lalwani worked at Cipla Ltd (NSE: CIPLA), a global pharmaceutical company, from May 2012 to August 2020 where he held positions of increasing responsibility, including CEO of Cipla USA, CEO of InvaGen, Head of US Strategy, M&A & Integration, and Head of Cipla’s Global Respiratory business. In these roles, Mr. Lalwani developed and executed multi-year strategic growth plans for key products and facilitated successful acquisitions as Cipla entered the specialty pharmaceutical space. Prior to Cipla, Mr. Lalwani was an Associate Partner with McKinsey & Company serving pharmaceutical and healthcare companies across the world, and an engineer with Medtronic. Mr. Lalwani holds a B.S. in Electrical Engineering from Georgia Institute of Technology and an M.B.A. from the Wharton School at the University of Pennsylvania.
HENRY GOSEBRUCH, Director
Mr. Gosebruch joined the Board in August 2026. He currently serves as Chief Executive Officer of Lakefront Biotherapeutics NV (formerly Galapagos NV) where he is also a member of the Board of Directors. From July 2023 to February 2025, he served as President and Chief Executive Officer of Neumora Therapeutics, Inc., a publicly traded neuroscience company. Prior to Neumora, from 2015 to 2023, Mr. Gosebruch was Executive Vice President and Chief Strategy Officer of AbbVie, where he built and led the company’s Corporate Strategy Office, spanning corporate strategy, competitive intelligence, business development and M&A, search and evaluation, alliance management, and AbbVie Ventures. Under his leadership, the group completed more than 100 transactions and investments, including AbbVie’s acquisition of Allergan. Earlier in his career, he spent more than 20 years at J.P. Morgan, most recently as Co-Head of North American M&A. Mr. Gosebruch serves on the Advisory Board of the University of Pennsylvania Life Sciences & Management Program. He holds a B.S. in Economics from the Wharton School at the University of Pennsylvania and is a certified public accountant.
MATTHEW J. LEONARD, R.Ph., Director
Mr. Leonard has been a member of the Board since August 2023. From December 2023 to August 2026, Mr. Leonard served as Senior Vice President, Global Access and Value, at Pfizer, Inc., where he was accountable for leading affordable and sustainable access for patients globally across the Pfizer portfolio. He previously served as the Chief Pharmacy Strategy Officer at Capsule, a digital healthcare company focused on improving the delivery of pharmacy services, and also as Executive Vice President, President North America, and Global Supply Chain Officer at Covetrus. Prior to Covetrus, Mr. Leonard spent 24 years in various leadership roles with CVS Health, most recently as Executive Vice President, Pharmaceutical Contracting, Purchasing and Managed Care. He also served as Chairman of the Board and President at Red Oak Sourcing, LLC, a joint venture between CVS Health and Cardinal Health, where he provided overall leadership and strategic direction for the organization, with responsibility for its business performance, operations, and the sourcing and procurement of generic pharmaceuticals. Mr. Leonard holds a B.S. in Pharmacy from the University of Rhode Island and is a Registered Pharmacist in the State of Rhode Island.
Member of the Audit and Finance Committee
ANTONIO PERA, Director
Mr. Pera has been a member of the Board since August 2020. He served as President of Par Pharmaceuticals Companies, Inc. (“Par”), the fifth-largest generic manufacturer in the United States, which is now part of Endo International, plc, from December 2013 until his retirement in August 2019. Prior to Par, Mr. Pera held leadership positions at AmerisourceBergen, American Pharmaceuticals Partners,
Bedford Laboratories, a division of Ben Venue Laboratories, and Baxter Healthcare. His breadth of experience spans sales, marketing, supply chain operations, and licensing, and he has played a pivotal role in the successful growth and commercialization efforts at several successful pharma entities. Mr. Pera holds a B.S. in Business Administration from the University of Illinois at Urbana-Champaign and an M.B.A. from DePaul University.
Chair of the Compensation Committee
DR. RENEE P. TANNENBAUM, Pharm.D., MBA
Dr. Tannenbaum joined the Board in March 2022. Dr. Tannenbaum currently serves as Head of Corporate Development for Bench International, an executive search firm focused on biotech and life sciences. She also serves as a strategic advisor for several biopharmaceutical and device companies and serves on the Cardiff Oncology, Inc. Board of Directors and as a Board Advisor to Aerami Therapeutics, Inc. She was previously Vice President of Global Partnering at Halozyme, Inc. and Head of Global Customer Excellence at AbbVie, where she was responsible for building commercial capabilities for the organization. Previously, Dr. Tannenbaum served as President of Myrtle Potter & Company, LLC, a global life sciences consulting and advisory firm and Executive Vice President and Chief Commercial Officer at Elan Pharmaceuticals, Inc. Prior to her role at Elan, Dr. Tannenbaum was at Novartis Pharma AG, where she led the Global Commercial Operations organization. She also spent nine years at Bristol-Myers Squibb and 16 years at Merck and Company, Inc. where she held a variety of leadership positions. Dr. Tannenbaum received her Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Sciences, her M.B.A. from Temple University, and her B.S in Pharmacy from the University of Connecticut.
Chair of the Nominating and Corporate Governance Committee
Member of the Compensation Committee
JEANNE THOMA, Director
Ms. Thoma has been a member of the Board since August 2020. Since December 2020, Ms. Thoma has served as a director of Avid Bioservices, Inc. In November 2021, Ms. Thoma joined the Board of Nanoform Finland Oyj, a producer of nanoformed
drug particles. In January 2022, Ms. Thoma joined the Board of Pharmathen Global
B.V. Previously, Ms. Thoma was on the Board of Vectura Group plc. from December
2020 until the sale of the company in October 2021. She is the former President and CEO of SPI Pharma Inc., a global pharmaceuticals ingredients company and an innovative solutions provider of ingredients and drug delivery systems. Prior to joining SPI in January 2017, Ms. Thoma worked at Lonza AG, a Switzerland-based biotech company, where she held positions of increasing responsibility, including President and COO of the Microbial Control Business Sector, and then as an independent consultant to various companies. Prior to joining Lonza in 2007, Ms. Thoma spent 14 years at BASF Corp. in the Pharma Solutions business where she held various leadership positions in Sales, Marketing and Operations. Ms. Thoma is a member of the Board of Advisors for the Drug Chemical and Associated Technologies Association. Ms. Thoma holds a B.S. from Montclair State University and an M.B.A. from Fairleigh Dickinson University.
Chair of the Audit and Finance Committee
Member of the Compensation Committee
